Helmerich & Payne Inc. Common Stock vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Helmerich & Payne Inc. Common Stock trades at $38.46 (market cap $3.91B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.15 (market cap $6.57B). The key difference: Iovance Biotherapeutics Inc. Common Stock is the larger of the two by market cap, and Helmerich & Payne Inc. Common Stock pays a 2.56% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Helmerich & Payne Inc. Common Stock for 0 Days and Iovance Biotherapeutics Inc. Common Stock for 1 Days on average.
| HP | IOVA | |
|---|---|---|
Market Cap | $3.91B | $6.57B |
Volume | 800,382 | 11,838,721 |
Sector | Energy | Health |
52-Week High | $47.64 | $14.82 |
52-Week Low | $23.11 | $1.81 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $5.54B | $6.50B |
Dividend Yield | 2.56% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Helmerich & Payne, Inc. is a US drilling contractor that designs, builds, and operates high-performance land and offshore drilling rigs for oil and gas producers worldwide.
Read more on HP →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →